SENSE: abSorbable vErsus Non-absorbable SuturEs for Wound Closure in Carpal Tunnel Release

Sponsor
Gelre Hospitals (Other)
Overall Status
Recruiting
CT.gov ID
NCT05431101
Collaborator
Deventer Ziekenhuis (Other)
2,604
2
2
59
1302
22.1

Study Details

Study Description

Brief Summary

Carpal Tunnel Syndrome is a prevalent condition, up to 9% in women and 0.6% in men. Surgical decompression in the most effective treatment. After surgery, approximately 1,8% of the patients develop a wound infection. Possibly, the type of sutures used can influence the prevalence of wound infection. In this RCT the incidence of infection is investigated between the use of absorbable versus non-absorbable sutures in carpal tunnel release.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Carpal Tunnel Release
N/A

Detailed Description

Carpal Tunnel Syndrome is a prevalent condition; up to 9% in women and 0.6% in men. It causes complaints of paresthesia, pain, numbness and loss of strength. Surgical decompression is the most effective treatment. After surgery, approximately 1,8% of the patients develop a wound infection. Possibly, the type of suture material which is used can influence the prevalence of wound infection. In current clinical practice both absorbable and non absorbable sutures are used. In literature, various hypothesis are described: Absorbable sutures could give more reaction of macrophages and therefore a higher chance on infection. This would not be the case for non-absorbable sutures, since they will be removed. However, in literature, there is still not enough evidence for superiority of absorbable or non-absorbable suture. In this RCT the incidence of infection is investigated between the use of absorbable versus non-absorbable sutures in carpal tunnel release.

The primary outcome is the ASEPSIS wound score. This will be scored by independent investigators.

Use of antibiotics, handtherapy and extra outpatient visits will be recorded.

Patients are asked to register their NRS scores the first three weeks after surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2604 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Absorbable Versus Non-absorbable Sutures for Wound Closure in Carpal Tunnel Release: a Randomized Controlled Trial
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2027
Anticipated Study Completion Date :
Apr 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Absorbable sutures

Absorbable sutures Vicryl rapide or Safil quick

Procedure: Carpal Tunnel Release
Transection of flexor retinaculum for patients who have carpal tunnel syndrome

Active Comparator: Non-absorbable sutures

Non-absorbable sutures Ethilon or Flexocrin

Procedure: Carpal Tunnel Release
Transection of flexor retinaculum for patients who have carpal tunnel syndrome

Outcome Measures

Primary Outcome Measures

  1. ASEPSIS wound score (Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and Stay as inpatient prolonged over 14 days) [10 to 14 days post surgery]

    score based on a picture made of the wound 10-14 days post carpal tunnel release. Minimum score 0, maximum score 70, score above 40 is categorized as wound infection

Secondary Outcome Measures

  1. NRS score (Numeric Rating Scale for pain) [until three weeks post surgery]

    pain score, minimum score 0, maximum score 10. Unbearable pain is scored as 10, no pain is scored as 0.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• indication for carpal tunnel release

Exclusion Criteria:
  • carpal tunnel syndrome which has yet been operated

  • injection with corticosteroids

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gelre Ziekenhuizen Apeldoorn Netherlands 7334DZ
2 Deventer Ziekenhuis Deventer Netherlands 7416SE

Sponsors and Collaborators

  • Gelre Hospitals
  • Deventer Ziekenhuis

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pauline Verhaegen, Doctor, Gelre Hospitals
ClinicalTrials.gov Identifier:
NCT05431101
Other Study ID Numbers:
  • 21/551
First Posted:
Jun 24, 2022
Last Update Posted:
Jul 1, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Pauline Verhaegen, Doctor, Gelre Hospitals
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 1, 2022